[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombosis-venous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombosis-venous":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,85,106,127,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100493864","bioimpedance-measurement-of-abdominal-free-flaps-during-arterial-and-venous-weaning-in-breast-reconstruction-100493864",false,"NCT05710705","Bioimpedance Measurement of Abdominal Free Flaps During Arterial and Venous Weaning in Breast Reconstruction","MONITRANS2","Inclusion Criteria:\n\n* Woman undergoing microsurgical breast reconstruction using a free abdominal flap\n* Age greater than or equal to 18 years\n\nExclusion Criteria:\n\n* Pregnant patient\n* Patient with an active implantable device such as a pacemaker or an artificial heart\n* Patient refusing to participate in the study\n* Age less than 18 years old","FEMALE","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","As the occurrence of thrombosis in post surgery is rare, it seemed difficult to study only this one. This is why we decided to test the bioimpedance, temperature and green, red and infrared light absorption measurements of the prototype during the weaning of the flap during surgery. Indeed, during weaning the investigators voluntarily interrupt the arterial and venous flow to transfer the flap to the breast. This weaning corresponds to a thrombosis model.\n\nThe patients will benefit from an \"improved\" postoperative monitoring. Indeed, in addition to the classical clinical monitoring, they will benefit from an additional monitoring during 5 days thanks to the realization of an ultrasound of the flap which will be carried out every 6 hours the first 24 hours then every 12 hours.\n\nThis protocol is therefore a feasibility study for the collection of data of interest.",[26,27,28],"Breast Reconstruction","Thrombosis, Venous","Bioimpedance Measurement Capacity",[30,27,31],"breast reconstruction","bioimpedance measurement capacity","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2022-12-08",{"date":40,"type":20},"2026-12",{"name":42,"class":43},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100633674","the-recana-for-lower-extremity-venous-obstructions-and-in-stent-restenosis-registry-100633674","NCT07529756","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry (\"The CALIBER Registry\")","CALIBER","INCLUSION CRITERA:\n\nA. Native Vessel:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Proximal lower extremity obstruction\u002Focclusion involving the femoral, common femoral, iliac veins, or inferior vena cava (IVC), alone or in combination that in the opinion of the investigator, treatment with the Recana would benefit the patient\n3. INC-3: Recana Thrombectomy Catheter System must enter vasculature\n4. INC-4: Willing and able to provide written informed consent\n\nB. In-Stent Restenosis:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Subjects with stents implanted greater than 6 weeks prior to index procedure\n3. INC-3: Location of thrombosed stents in proximal lower extremity deep vein segments including common femoral, external iliac, common iliac vein, or inferior vena cava alone or in combination that in the opinion of the investigator treatment with the Recana would benefit the patient\n4. INC-4: Recana Thrombectomy Catheter System must enter vasculature\n5. INC-5: Willing and able to provide written informed consent\n\nEXCLUSION CRITERA\n\nA. Native Vessel:\n\n1. EXC-1: IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n2. EXC-2: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n3. EXC-3: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n4. EXC-4: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n5. EXC-5: Severe, life-threatening allergy to iodine or contrast dye\n6. EXC-6: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n7. EXC-7: Life expectancy less than 1 year\n8. EXC-8: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n9. EXC-9: Known hypercoagulable states that, in the opinion of the investigator, cannot be medically managed throughout the study period\n10. EXC-10: Inability to secure venous access and cross lesion\n11. EXC-11: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n12. EXC-12: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed\n\nB. In-Stent Restenosis:\n\n1. EXC-1: Exposed stents with broken struts, significantly deformed struts, struts protruding into the vessel\n2. EXC-2: Stent failure caused by undersizing or malapposition of the stent(s) \\[For example, the segment of a stent in the iliac vein that is not wall apposed or cannot be apposed to the wall after balloon dilation is excluded. The segment of a stent that extends into the IVC that is not wall apposed would not be excluded.\\]\n3. EXC-3: Stents compressed to \\\u003C6mm that remain \\\u003C6mm after balloon dilation\n4. EXC-4: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n5. EXC-5: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n6. EXC-6: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n7. EXC-7: Severe, life-threatening allergy to iodine or contrast dye\n8. EXC-8: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n9. EXC-9: Life expectancy less than 1 year\n10. EXC-10: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n11. EXC-11: Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n12. EXC-12: Inability to secure venous access and cross lesion\n13. EXC-13: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n14. EXC-14: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed","ALL",{"count":55,"type":20},87,"1 Year","OBSERVATIONAL","The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions. The main questions the study aims to answer are:\n\n* What is the observed rate of safety events through the 30-day follow-up?\n* What is the rate of technical success (acute procedural success) achieved at the index procedure?\n\nParticipants already undergoing treatment with the Recana as part of their regular medical care will be followed for 1 year.",[60,61,62,63,27,64,65],"Chronic Venous Disease","Chronic Venous Insufficiency, CVI","Venous Thrombosis","Thrombosis (Stent Thrombosis)","Embolism and Thrombosis","Thrombectomy",[67,68,69,70,71,72,73],"in-stent restenosis","venous obstruction or occlusion","thrombus","emboli","CALIBER Registry","recanalization","debulking","NOT_YET_RECRUITING","2026-05-07",{"date":77,"type":36},"2026-05-12",{"date":79,"type":20},"2026-06",{"date":81,"type":20},"2029-03",{"name":83,"class":84},"Intervene, Inc.","INDUSTRY",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":44},"100592846","the-impact-of-mtm-model-on-the-efficacy-and-safety-of-anticoagulant-therapy-in-postoperative-colorectal-cancer-patients-100592846","NCT06998745","The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients","Inclusion Criteria:\n\n1. Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.\n2. CRC patients with VTE treated with an anticoagulant for at least 3 moths.\n\nExclusion Criteria:\n\n1.Participation in this study required active anticoagulant treatment. Apart from this, there were no specific exclusion criteria.","100 Years",{"count":93,"type":20},327,[23],"Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high probability of recurrent VTE and bleeding during anticoagulation therapy.The Medication Therapy Management (MTM) model will contribute to reducing ADEs associated with anticoagulants in CRC patients.",[27],"2025-05-22",{"date":99,"type":36},"2025-05-31",{"date":101,"type":36},"2025-05-01",{"date":103,"type":20},"2027-12-30",{"name":105,"class":43},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":44},"100542932","venous-thrombosis-after-removal-of-central-venous-catheter-100542932","NCT06349291","Venous Thrombosis After Removal of Central Venous Catheter","Venous Thrombosis After Removal of Central Venous Catheter-prospective Observational Study","Inclusion Criteria: Patients who were admitted to the intensive care unit and had a central catheter inserted during their stay in the unit for any reason, and whose central catheter was removed during their stay in the general intensive care unit.\n\n\\-\n\nExclusion Criteria:Patients whose insertion or removal of the central catheter did not occur during the hospitalization in the intensive care unit, patients who were treated with full anticoagulation in the intensive care unit.\n\n\\-","99 Years",{"count":115,"type":20},100,"Insertion of intravenous catheter is a very common operation in patients in the general intensive care unit. These catheters are used for a variety of purposes - administration of inotropics\u002Fpressors, intravenous nutrition, concentrated electrolytes and performing dialysis.There are several known complications of central venous catheter insertion, such as thrombosis and pulmonary embolism. In a literature review, there are no clear data regarding the rate of intravenous thrombosis in patients after removal of a central venous catheter. These findings are often discovered randomly, when the patient undergoes imaging for a different indication. There is no recommendation for an active search for intravenous thrombi at the catheter insertion sites in these patients, and it is not entirely clear whether it is mandatory to administer anticoagulant treatment in these patients if thrombi are randomly discovered at the catheter insertion sites.\n\nIn this study, we aim to check the proportion of patients who developed thrombosis at the central catheter insertion sites after its removal, to check whether there are catheter insertion sites that are at a higher risk of developing thrombosis than other sites, and to check whether there are predictive characteristics for the development of this type of thrombosis.",[27],"2025-05-07",{"date":120,"type":36},"2025-05-13",{"date":122,"type":36},"2024-11-01",{"date":124,"type":20},"2025-08-01",{"name":126,"class":43},"Meir Medical Center",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":44},"100538290","acute-and-subacute-iliofemoral-andor-caval-deep-vein-thrombosis-evaluation-of-mechanical-thrombectomy-systems-100538290","NCT06288906","Acute and Subacute Iliofemoral and\u002For Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems","Acute and Subacute Iliofemoral and\u002For Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems in a Monocentric, Observational Retrospective and Prospective Study (ASTER Study)","ASTER","Inclusion Criteria:\n\nAll patients admitted in the Unit of Vascular Surgery with proximal DVT (inferior vena cava, and\u002For iliac vein, and\u002For common femoral vein, and\u002For deep femoral vein, and\u002For femoral vein), according to ESVS guidelines (2022).\n\nExclusion Criteria:\n\n* Patient treated with thrombolysis drugs within 48 hours prior to the index procedure\n* Active bleeding, recent (\\\u003C3 months) gastrointestinal (GI) bleeding, active peptic ulcer, severe liver dysfunction, and bleeding diathesis\n* Impossibility or refusal to give informed consent",{"count":136,"type":20},50,"This is a physician-initiated, observational, monocentric, retrospective and prospective Study. The study is intended to assess the feasibility of mechanical thrombectomy of caval and iliofemoral veins according to normal clinical practice in adult patients with symptomatic acute or subacute ileofemoral or caval deep vein thrombosis objectively diagnosed with CT scan imaging.",[27],"2025-04-29",{"date":101,"type":36},{"date":142,"type":36},"2025-03-30",{"date":144,"type":20},"2027-12",{"name":146,"class":43},"IRCCS San Raffaele",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":44},"100527574","phase-3-evaluate-the-efficacy-and-safety-of-edoxaban-on-prevention-of-catheter-related-thrombosis-crt-in-cancer-patients-100527574","NCT06149533","Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients","A Randomized, Multicenter, Open-Label, Control, Clinical Trial to Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients","Thrombosis","Inclusion Criteria:\n\n1. Age≥18.\n2. Cancer patients with a catheter-related thrombus risk prediction model score ≥ 19.6.\n3. ECOG score≤2.\n4. Expected survival period over 6 months.\n5. Malignant tumor was diagnosed by pathology and central venous catheterization was successfully completed.\n6. Signing of informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Unknown location of the primary tumor.\n2. Allergy to the active ingredient of edoxaban tablets or other excipients.\n3. There is clinically significant active bleeding.\n4. Platelet \\\u003C50×109\u002FL.\n5. Liver disease with coagulopathy or clinically relevant bleeding risk.\n6. A lesion or condition with a significant risk of major bleeding, such as current or recent gastrointestinal ulcer, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial hemorrhage, esophageal varices, arteriovenous malformations, vascular aneurysms, or major intravertebral or intracerebral vascular malformations.\n7. Concomitant therapy with any other anticoagulant, such as Unfractionated heparin (UFH), Low molecular heparin (Low molecular weight heparin, LMWH) (enoxaparin, dalteparin, etc.), heparin derivative (fondaparinux, etc.), oral anticoagulant (warfarin, dabigatran, rivaroxaban, apixaban, etc.), except in the special case of administration of UFH to maintain central venous catheter patency.\n8. Surgical treatment is planned for the duration of the study.\n9. Uncontrolled co-morbidities include, but are not limited to:\n\n   Serious, uncontrolled infection. Symptomatic heart failure (New York Heart Association class II-IV) or symptomatic or poorly controlled arrhythmias Uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) despite standard treatment.\n\n   Any arterial thromboembolic event within 6 months before enrollment. Tumor invasion of large vessels. History of deep vein thrombosis, pulmonary embolism, or other major thromboembolism within 3 months before enrollment.\n10. History of gastrointestinal perforation within 6 months before enrollment.\n11. Pregnant or breastfeeding women.\n12. Oral contraceptives.\n13. Conditions considered unsuitable for inclusion in this study.",{"count":156,"type":20},366,[158],"PHASE3","To evaluate the efficacy and safety of edoxaban in the prevention of tumor catheter-related thrombosis (CVC\u002FPICC) in high-risk patients",[27,161,162],"Cancer","Catheter Complications",[164,165,161,166],"Prevention","Catheter-related Thrombosis","Edoxaban","2023-11-20",{"date":169,"type":36},"2023-11-29",{"date":171,"type":20},"2023-11-30",{"date":173,"type":20},"2026-11-30",{"name":175,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]